

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE
2022 ANNUAL REPORT**

Reference is made to the annual report of Lansens Pharmaceutical Holdings Limited (the “**Company**”, together with the subsidiaries, the “**Group**”) for the year ended 31 December 2022 (the “**2022 Annual Report**”) which was published on 20 April 2023. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those set out in the 2022 Annual Report.

The Company would like to provide the following supplemental information in relation to the placing of 49,520,000 new shares under general mandate which was completed last year on 20 April 2022 (the “**Placing**”). This supplemental announcement should be read in conjunction with the 2022 Annual Report.

Fundraising

Reasons for the Placing

As disclosed in the announcement of the Company dated 7 April 2022, the reasons for the Placing were to raise funds for the Group’s business development as the Company proposed to use such net proceeds from the Placing for (i) potential future acquisitions or projects, and (ii) replenishment of working capital and general corporate purposes to support the Company’s strategy.

The then closing price at the date of subscription agreement

As disclosed in the announcement of the Company dated 7 April 2022, the placing price of HK\$1.20 per placing share represents a premium of approximately 11.1% to the then closing price of HK\$1.08 per Share as quoted on the Stock Exchange on 7 April 2022, being the date of the subscription agreement entered between the Company and the places in relation to the Placing.

Use of proceeds

As disclosed in the announcement of the Company dated 7 April 2022, the gross and net proceeds from the Placing were US\$7.7 million and US\$7.6 million respectively.

As disclosed in the 2022 Annual Report, approximately US\$5.6 million of the net proceeds was utilised as working capital during the year ended 31 December 2022, and the intended use of the remaining balance of the net proceeds of US\$2.0 million remained unchanged as disclosed in the announcement of the Company dated 7 April 2022, namely for (i) potential future acquisitions or projects and (ii) replenishment of working capital and general corporate purposes to support the Company's strategy. As disclosed in the 2022 Annual Report, there is no specific timeline for the use of the remaining balance of the net proceeds as this is subject to the availability of suitable investment opportunities, the pace of the Company's business development, and the economic and market conditions of the pharmaceutical industry in China.

As at the date of this announcement, the Company would like to further update that, since no suitable investment opportunity has been identified, the remaining net proceeds were fully utilised as working capital to support the Company's strategy. Of the total net proceeds amounting to US\$7.6 million, approximately US\$6.1 million was utilised as payments for procurement of one of the Group's key products from a supplier, related freight costs and other related expenses, approximately US\$1.3 million was utilised as administrative expenses, and approximately US\$0.2 was allocated for professional fees and other fees.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 31 July 2023

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun.